Abstract
Ewing’s sarcoma (EWS) is the second most common primary bone tumor in pediatric patients characterized by over expression of CD99. Current management consists in extensive chemotherapy in addition to surgical resection and/or radiation. Recent improvements in treatment are still overshadowed by severe side effects such as toxicity and risk of secondary malignancies; therefore, more effective strategies are urgently needed. The goal of this work was to develop a rapid, inexpensive, and “up-scalable” process of a novel human bivalent single-chain fragment variable diabody (C7 dAbd) directed against CD99, as a new therapeutic approach for EWS. We first investigated different Escherichia coli constructs of C7 dAbd in small-scale studies. Starting from 60 % soluble fraction, we obtained a yield of 25 mg C7 dAbd per liter of bacterial culture with the construct containing pelB signal sequence. In contrast, a low recovery of C7 dAbd was achieved starting from periplasmic inclusion bodies. In order to maximize the yield of C7 dAbd, large-scale fermentation was optimized. We obtained from 75 % soluble fraction 35 mg C7 dAbd per L of cell culture grown in a synthetic media containing 3 g/L of vegetable peptone and 1 g/L of yeast extract. Furthermore, we demonstrated the better efficacy of the cell lysis by homogenization versus periplasmic extraction, in reducing endotoxin level of the C7 dAbd. For gram-scale purification, a direct aligned two-step chromatography cascade based on binding selectivity was developed. Finally, we recovered C7 dAbd with low residual process-related impurities, excellent reactivity, and apoptotic ability against EWS cells.
Similar content being viewed by others
References
Bagnara GP, Serra M, Giovannini M, Badiali M, Stella M, Montaldi A, Granchi D, Paolucci P, Rocchi P, Pession A, Paolucci G, Stella M, Montaldi A, Tessarollo L, Cavazzana AO (1990) Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). Int J Cell Cloning 8(6):409–424
Bernard G, Zoccola D, Deckert M, Breittmayer JP, Aussel C, Bernard A (1995) The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4 + CD8+ thymocytes. J Immunol 154(1):26–32
Brenke R, Hall DR, Chuang GY, Comeau SR, Bohnuud T, Beglov D, Schueler-Furman O, Vajda S, Kozakov D (2012) Application of asymmetric statistical potentials to antibody-protein docking. Bioinformatics 28(20):2608–2614
Carter PJ (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1(2):118–129
Champion KM, Nishihara JC, Joly JC, Arnott D (2001) Similarity of the Escherichia coli proteome upon completion of different biopharmaceutical fermentation processes. Proteomics 1(9):1133–1148
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185
Donaldson SS (2004) Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer 42(5):471–476
Duchman KR, Gao Y, Miller BJ (2015) Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 39(2):189–195
Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A (2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Factories 8:17
Frenzel A, Hust M, Schirrmann T (2013) Expression of recombinant antibodies. Front Immunol 4:217
Gellini M, Ascione A, Flego M, Mallano A, Dupuis ML, Zamboni S, Terrinoni M, D'Alessio V, Manara MC, Scotlandi K, Picci P, Cianfriglia M (2013) Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing’s Sarcoma tumor cells. Curr Pharm Biotechnol 14(4):449–463
Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K (2015) CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. Clin Cancer Res 21:146–156
Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, Peter K (2009) Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 101(6):1012–1019
Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, Chung DH, Kim TJ, Lee WJ, Park CK, Ree HJ, Park SH (1997) CD99 (MIC2) regulates theLFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 159(5):2250–2258
Hamilton SN, Carlson R, Hasan H, Rassekh SR, Goddard K (2015) Long-term outcomes and complications in pediatric Ewing sarcoma. Am J Clin Oncol. doi:10.1097/COC.0000000000000176
Henderikx P, Kandilogiannaki M, Petrarca C, Von Mensdorff Pouilly S, Hilgers JH, Krambovitis E, Arends JW, Hoogenboom HR (1998) Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 58(19):4324–4332
Hoffman LM, Gore L (2014) Blinatumomab, a bi-specific anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 4:63
Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136
Huang CJ, Lin H, Yang X (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39(3):383–399
Kamionka M (2011) Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol 12(2):268–274
Katsuda T, Sonoda H, Kumada Y, Yamaji H (2012) Production of antibody fragments in Escherichia coli. Methods Mol Biol 907:305–324
Kelley LA, Sternberg MJE (2009) Protein structure prediction on the web: a case study using the Phyre server. Nat Protoc 4(3):363–371
King DJ, Byron OD, Mountain A, Weir N, Harvey A, Lawson AD, Proudfoot KA, Baldock D, Harding SE, Yarranton GT, Owens RJ (1993) Expression, purification and characterization of B72.3 Fv fragments. Biochem J 290(Pt 3):723–729
Kipriyanov SM (2009) High-level periplasmic expression and purification of scFvs. Methods Mol Biol 562:205–214
Kontermann RE (2010) Alternative antibody formats. Curr Opin Mol Ther 12(2):176–183
Kuo TT, Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3(5):422–430
Laemmli UK (1970) Cleavage of a structural protein during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685
Lee J, Lee J, Hwang H, Jung E, Huh S, Hyun J, Park D (2009) Promotion of stem cell proliferation by vegetable peptone. Cell Prolif 42(5):595–601
Liebner DA (2015) The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J Surg Oncol 111(5):622–631
Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C (2012) Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer 118(20):5050–5059
Marchetti S, Schellens JHM (2007) The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 97(5):577–581
Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ (2005) Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif 42(2):255–267
Mirick GR, Bradt BM, Denardo SJ, Denardo GL (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Q J Nucl Med Mol Imaging 48(4):251–257
Moore DD, Haydon RC (2014) Ewing’s sarcoma of bone. Cancer Treat Res 162:93–115
Moricoli D, Laguardia ME, Carbonella DC, Balducci MC, Dominici S, Fiori V, Serafini G, Flego M, Cianfriglia M, Magnani M (2014a) Isolation of a new human scFv antibody recognizing a cell surface binding site to CEACAM1. Large yield production, purification and characterization in E. coli expression system. Protein Expr Purif 93:38–45
Moricoli D, Muller WA, Carbonella DC, Balducci MC, Dominici S, Watson R, Fiori V, Weber E, Cianfriglia M, Scotlandi K, Magnani M (2014b) Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system. J Immunol Methods 408:35–45
Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27(4):331–337
Presta LG (2005) Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 116(4):731–736
Reichert JM (2015) Antibodies to watch in 2015. MAbs 7(1):1–8
Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65(4):1471–1478
Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K (2010) CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 120(3):668–680
Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA (2002) CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 3(2):143–150
Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M, Baldini N (1996) Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56(10):2434–2439
Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, Lollini PL, Nanni P, Nicoletti G, Bernard G, Bernard A, Picci P (2000) CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60(18):5134–5142
Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A, Manara MC, Benini S, Bernard A, Picci P (2006) Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur J Cancer 42(1):91–96
Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, Yansura DG (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263(1–2):133–147
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228(4705):1315–1317
Smith MJ, Goodfellow PJ, Goodfellow PN (1993) The genomic organization of the human pseudoautosomal gene MIC2 and the detection of a related locus. Hum Molec Genet 2(4):417–422
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, Smith FO, Reaman GH, Smith MA, Seibel NL (2010) Outcomes for children and adolescent with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625–2634
Suh YH, Shin YK, Kook MC, Oh KI, Park WS, Kim SH, Lee IS, Park HJ, Huh TL, Park SH (2003) Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene 307:63–76
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493–2498
Towbin H, Staehelin Gordon TJ (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76(4):4350–4354
Walls D, Loughran ST (2011) Tagging recombinant proteins to enhance solubility and aid purification. Methods Mol Biol 681:151–175
Weidner N, Tjoe J (1994) Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/p32MIC2 and is useful in diagnosing Ewing’s sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 18(5):486–494
Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Plückthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59(22):5758–5767
Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455
Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ (2015) Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 7(3):470–482
Acknowledgments
We are thankful to Dr. Lisa Pucci (Diatheva) for residual DNA analysis and Dr. Claudia Gabucci (University of Urbino) and Dr. Luca Micci (Emory University) for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Funding
This study was supported by grant from the Italian Association for Cancer Research (Katia Scotlandi—AIRC Project N.14049).
Conflict of interest
Diego Moricoli, Damiano Cosimo Carbonella, Sabrina Dominici, Valentina Fiori, Maria Cristina Balducci and Maria Elena Laguardia are Diatheva s.r.l employees. Mauro Magnani has Diatheva stock and/or warrants. No potential conflicts of interest were disclosed by the other authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 388 kb)
Rights and permissions
About this article
Cite this article
Moricoli, D., Carbonella, D.C., Dominici, S. et al. Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing’s sarcoma. Appl Microbiol Biotechnol 100, 3949–3963 (2016). https://doi.org/10.1007/s00253-015-7226-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-015-7226-5